| Literature DB >> 26565916 |
Bingchen Han1, Ying Qu1, Yanli Jin1, Yi Yu1, Nan Deng2, Kolja Wawrowsky3, Xiao Zhang2, Na Li4, Shikha Bose5, Qiang Wang6, Sugunadevi Sakkiah7, Ravinder Abrol7, Tor W Jensen8, Benjamin P Berman6, Hisashi Tanaka1, Jeffrey Johnson1, Bowen Gao1, Jijun Hao9, Zhenqiu Liu2, Ralph Buttyan10, Partha S Ray8, Mien-Chie Hung11, Armando E Giuliano1, Xiaojiang Cui12.
Abstract
The mesoderm- and epithelial-mesenchymal transition-associated transcription factor FOXC1 is specifically overexpressed in basal-like breast cancer (BLBC), but its biochemical function is not understood. Here, we demonstrate that FOXC1 controls cancer stem cell (CSC) properties enriched in BLBC cells via activation of Smoothened (SMO)-independent Hedgehog (Hh) signaling. This non-canonical activation of Hh is specifically mediated by Gli2. Furthermore, we show that the N-terminal domain of FOXC1 (aa 1-68) binds directly to an internal region (aa 898-1168) of Gli2, enhancing the DNA-binding and transcription-activating capacity of Gli2. FOXC1 expression correlates with that of Gli2 and its targets in human breast cancers. Moreover, FOXC1 overexpression reduces sensitivity to anti-Hedgehog (Hh) inhibitors in BLBC cells and xenograft tumors. Together, these findings reveal FOXC1-mediated non-canonical Hh signaling that determines the BLBC stem-like phenotype and anti-Hh sensitivity, supporting inhibition of FOXC1 pathways as potential approaches for improving BLBC treatment.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26565916 PMCID: PMC4806384 DOI: 10.1016/j.celrep.2015.09.063
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423